Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRT 2527

Next Previous
Drug Profile

PRT 2527

Alternative Names: PRT-2527

Latest Information Update: 25 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Prelude Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome; Solid tumours; T-cell lymphoma

Most Recent Events

  • 25 May 2026 Discontinued - Phase-I for Chronic lymphocytic leukaemia (In adults, In the elderly, Combination therapy) in USA (IV)
  • 25 May 2026 Discontinued - Phase-I for Chronic lymphocytic leukaemia (In adults, Monotherapy, In the elderly) in Poland (IV)
  • 25 May 2026 Discontinued - Phase-I for Chronic lymphocytic leukaemia (In the elderly, Monotherapy, In adults) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top